Advertisement
"We are very pleased to appoint Kevin Stark as our CEO," said Jay Lichter,Ph.D., Chairman of the Board. "We believe his experience, which spans basicresearch to executive management, will be instrumental as the company advancesinto drug development and seeks potential partnerships."
Advertisement
Dr. Stark received a Ph.D. in Pharmacology from the University ofWashington, and a B.S. in Zoology from Colorado State University.
InCode also announced that William St. John has resigned as President andChief Executive Officer, and will remain on the Board of Directors.
"We are very grateful to Bill for his vision in recognizing the promise ofcomplement depletion in human disease, and his role in building the company tothis point," said Carl-Wilhelm Vogel, MD, Ph.D., Founder and Board Member,from the Cancer Research Center of Hawaii.
In conjunction with this transition, the company will shift operationsfrom the San Francisco, CA location to the Thousand Oaks, CA area.
About InCode
InCode's novel approach is focused on the selective interruption of thecomplement cascade. Activation of the complement cascade has been implicatedin the pathogenesis of many inflammatory diseases, including rheumatoidarthritis, asthma, ischemia-reperfusion injury and age-related maculardegeneration. Importantly, there is increased appreciation for the role ofcomplement in certain types of cancer.
This release was issued through eReleases(TM). For more information,visit http://www.ereleases.com.For more information, contact: [email protected] http://www.incodebp.com
SOURCE InCode BioPharmaceutics, Inc.
